Skip to Content
Merck
  • Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.

Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.

Journal of medicinal chemistry (2013-06-19)
Irene T Weber, Mary Jo Waltman, Marat Mustyakimov, Matthew P Blakeley, David A Keen, Arun K Ghosh, Paul Langan, Andrey Y Kovalevsky
ABSTRACT

HIV-1 protease is an important target for the development of antiviral inhibitors to treat AIDS. A room-temperature joint X-ray/neutron structure of the protease in complex with clinical drug amprenavir has been determined at 2.0 Å resolution. The structure provides direct determination of hydrogen atom positions in the enzyme active site. Analysis of the enzyme-drug interactions suggests that some hydrogen bonds may be weaker than deduced from the non-hydrogen interatomic distances. This information may be valuable for the design of improved protease inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Amprenavir, ≥98% (HPLC)